Evidence map›Paper›PMID 40107179›Full record

ArticleBiomaterials2025

Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer.

Sudipta Panja, Ekta Kapoor, Kasturi Siddhanta, Chinmay M Jogdeo, Diptesh Sil, Rubayat I Khan, Neha Kumari, Ling Ding, Howard E Gendelman, Amar B Singh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sudipta PanjaCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA; Department of Pharmacology and Experimental Neuroscience, USA.
Ekta KapoorCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Kasturi SiddhantaCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Chinmay M JogdeoCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Diptesh SilCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Rubayat I KhanCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Neha KumariCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Ling DingCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, USA.
Amar B SinghDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
David OupickýCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, USA. Electronic address: david.oupicky@unmc.edu.

Funding

Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel diseaseR01DK124095 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID, SINGH, AMAR B · 2020 to 2023
$2.1M
Development of siRNA conjugates for combination treatment of acute kidney injuryR01DK120533 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID, PADANILAM, BABU JOSEPH · 2018 to 2022
$2.1M
NIDDK NIH HHS R01 DK120533NIDDK NIH HHS R01 DK124095
6 · The paper itself

Abstract

The intractable and devastating nature of pancreatic ductal adenocarcinoma (PDAC) necessitates an urgent need for novel therapies. This study presents the development of a novel polymer prodrug system for the combination treatment of PDAC, based on an optimized pharmacologically active anti-metastatic macromolecular carrier, PCQ, conjugated with gemcitabine (GEM). Structure-activity relationship evaluations showed that random PCQ copolymers exhibited superior anti-migratory activity compared to the gradient PCQ analogs. GEM was incorporated into the random PCQ copolymers using disulfide linker to prepare a reduction-responsive prodrug, PCQ(r)6-SS-GEM12. The resultant therapeutic system presents a pharmacologically active delivery strategy that targets both the proliferative and the metastatic phenotype in PDAC. The PCQ(r)6-SS-GEM12 prodrug demonstrated a selective release of GEM under the reductive tumor environment leading to a significant inhibition of tumor growth with pronounced anti-metastatic effect. Collectively, our data show that the combination of anti-metastatic PCQ and cytotoxic GEM-based reduction-responsive prodrug polymer offers an innovative strategy to treat PDAC.

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalDeoxycytidinePancreatic NeoplasmsPolymersProdrugsAnimalsCell Line, TumorCell MovementCell ProliferationGemcitabineHumansMiceMice, NudeNeoplasm MetastasisAntineoplastic AgentsDeoxycytidineGemcitabinePolymersProdrugsDrug deliveryMetastasisPancreatic ductal adenocarcinomaPolymeric drugRedox-responsive prodrugSelf-assembly

Identifiers

PMID40107179
PMCPMC13502512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.